Severe hypertension development significantly improves progression-free survival in regorafenib treatment for metastatic colorectal cancer

被引：0
|
作者：
Yoshitaka Saito
Yoh Takekuma
Yoshito Komatsu
Mitsuru Sugawara
机构：
[1] Hokkaido University Hospital,Department of Pharmacy
[2] Hokkaido University Hospital,Cancer Center
[3] Hokkaido University,Laboratory of Pharmacokinetics, Faculty of Pharmaceutical Sciences
来源：
International Journal of Clinical Oncology | 2023年 / 28卷
关键词：
Regorafenib; Severe hypertension; Metastatic colorectal cancer (mCRC); Vascular endothelial growth factor (VEGF); Progression-free survival; Multikinase inhibitor;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1183 / 1190
页数：7
相关论文
共 50 条
  • [41] Progression-free Survival as a Surrogate End-point in Advanced Colorectal Cancer Treated with Antiangiogenic Therapies
    Montagnani, Francesco
    Di Leonardo, Greta
    Pino, Maria Simona
    Martella, Francesca
    Perboni, Simona
    Ribecco, Angela
    Fioretto, Luisa
    ANTICANCER RESEARCH, 2016, 36 (08) : 4259 - 4265
  • [42] Prognostic significance of sarcopenia diagnosed based on the anthropometric equation for progression-free survival and overall survival in patients with colorectal cancer
    Xie, Hailun
    Wei, Lishuang
    Gao, Shunhui
    Liu, Mingxiang
    Liang, Yanren
    Yuan, Guanghui
    Wang, Qiwen
    Xu, Yansong
    Tang, Shuangyi
    Gan, Jialiang
    FRONTIERS IN NUTRITION, 2023, 10
  • [43] Progression-Free Survival as a Surrogate Endpoint of Overall Survival in Patients With Metastatic Renal Cell Carcinoma
    Halabi, Susan
    Rini, Brian
    Escudier, Bernard
    Stadler, Walter M.
    Small, Eric J.
    CANCER, 2014, 120 (01) : 52 - 60
  • [44] Lenvatinib as first-line treatment for advanced thyroid cancer: long progression-free survival
    Simone De Leo
    Marta Di Stefano
    Luca Persani
    Laura Fugazzola
    Carla Colombo
    Endocrine, 2021, 72 : 462 - 469
  • [45] Association of Hand-Foot Skin Reaction with Regorafenib Efficacy in the Treatment of Metastatic Colorectal Cancer
    Kobayashi, Kazuo
    Kawakami, Kazuyoshi
    Yokokawa, Takashi
    Aoyama, Takeshi
    Suzuki, Kenichi
    Wakatsuki, Takeru
    Suenaga, Mitsukuni
    Sato, Hitoshi
    Sugiyama, Erika
    Yamaguchi, Kensei
    Hama, Toshihiro
    ONCOLOGY, 2019, 96 (04) : 200 - 206
  • [46] Association between cytokines and progression-free survival in ovarian cancer following CRS/HIPEC treatment
    Chen, Chao-Yu
    Wang, Ting-Yao
    Liu, Jing-Lan
    Ou, Yu-Che
    Lee, Li-Wen
    Hung, Chien-Hui
    Lee, Chuan-Pin
    Lung, Jrhau
    JOURNAL OF OVARIAN RESEARCH, 2025, 18 (01)
  • [47] Evaluation of progression-free survival as a surrogate endpoint for overall survival in locally advanced or metastatic differentiated thyroid cancer: a systematic review
    Shijie Yang
    Jing Zhan
    Xiequn Xu
    Endocrine, 2023, 82 : 491 - 497
  • [48] Lenvatinib as first-line treatment for advanced thyroid cancer: long progression-free survival
    De Leo, Simone
    Di Stefano, Marta
    Persani, Luca
    Fugazzola, Laura
    Colombo, Carla
    ENDOCRINE, 2021, 72 (02) : 462 - 469
  • [49] Evaluation of progression-free survival as a surrogate endpoint for overall survival in locally advanced or metastatic differentiated thyroid cancer: a systematic review
    Yang, Shijie
    Zhan, Jing
    Xu, Xiequn
    ENDOCRINE, 2023, 82 (03) : 491 - 497
  • [50] Identification and Validation of an m6A-Related LncRNA Signature to Predict Progression-Free Survival in Colorectal Cancer
    Zhang, Yong
    Li, Lu
    Chu, Feifei
    Xiao, Xingguo
    Zhang, Li
    Li, Kunkun
    Wu, Huili
    PATHOLOGY & ONCOLOGY RESEARCH, 2022, 28
12345